Market Overview: Breast Cancer   29-page PDF document
$299.00

Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Breast Cancer (PDF)

PDF document 29 Pages

$299.00

Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF THIS PDF DOCUMENT

  1. The breast cancer therapy market was the largest in oncology across the major markets
  2. Etiology and Pathophysiology
  3. Key Pathways and Drug Targets

HEALTHCARE PDF DESCRIPTION

This product (Market Overview: Breast Cancer) is a 29-page PDF document, which you can download immediately upon purchase.

The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025.

Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer's CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent's sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai's HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Breast Cancer PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

You must be logged in to contact the author.

Click here to log in Click here register

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"FlevyPro provides business frameworks from many of the global giants in management consulting that allow you to provide best in class solutions for your clients."

– David Harris, Managing Director at Futures Strategy
 
"As a young consulting firm, requests for input from clients vary and it's sometimes impossible to provide expert solutions across a broad spectrum of requirements. That was before I discovered Flevy.com.

Through subscription to this invaluable site of a plethora of topics that are key and crucial to consulting, I "

– Nishi Singh, Strategist and MD at NSP Consultants
 
"As a consultant requiring up to date and professional material that will be of value and use to my clients, I find Flevy a very reliable resource.

The variety and quality of material available through Flevy offers a very useful and commanding source for information. Using Flevy saves me time, enhances my expertise and ends up being a good decision."

– Dennis Gershowitz, Principal at DG Associates
 
"I am extremely grateful for the proactiveness and eagerness to help and I would gladly recommend the Flevy team if you are looking for data and toolkits to help you work through business solutions."

– Trevor Booth, Partner, Fast Forward Consulting
 
"I have used Flevy services for a number of years and have never, ever been disappointed. As a matter of fact, David and his team continue, time after time, to impress me with their willingness to assist and in the real sense of the word. I have concluded in fact "

– Roberto Pelliccia, Senior Executive in International Hospitality
 
"Flevy.com has proven to be an invaluable resource library to our Independent Management Consultancy, supporting and enabling us to better serve our enterprise clients.

The value derived from our [FlevyPro] subscription in terms of the business it has helped to gain far exceeds the investment made, making a subscription a no-brainer for any growing consultancy – or in-house strategy team."

– Dean Carlton, Chief Transformation Officer, Global Village Transformations Pty Ltd.
 
"As an Independent Management Consultant, I find Flevy to add great value as a source of best practices, templates and information on new trends. Flevy has matured and the quality and quantity of the library is excellent. Lastly the price charged is reasonable, creating a win-win value for "

– Jim Schoen, Principal at FRC Group
 
"Flevy is now a part of my business routine. I visit Flevy at least 3 times each month.

Flevy has become my preferred learning source, because what it provides is practical, current, and useful in this era where the business world is being rewritten.

In today's environment where there are so "

– Omar HernĂ¡n Montes Parra, CEO at Quantum SFE


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Value Chain Analysis Integrated Financial Model

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.